Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer

Shuichi Matsumura; Mikihito Nakamori; Toshiaki Tsuji; Tomoya Kato; Masaki Nakamura; Toshiyasu Ojima; Hiroshi Fukuhara; Yasushi Ino; Tomoki Todo; Hiroki Yamaue

doi:10.18632/oncotarget.27873

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer

Shuichi Matsumura, Mikihito Nakamori _, Toshiaki Tsuji, Tomoya Kato, Masaki Nakamura, Toshiyasu Ojima, Hiroshi Fukuhara, Yasushi Ino, Tomoki Todo and Hiroki Yamaue

PDF | Full Text | How to cite

Oncotarget. 2021; 12:344-354. https://doi.org/10.18632/oncotarget.27873

Metrics: PDF 1353 views | Full Text 2484 views | ?

Abstract

Shuichi Matsumura1, Mikihito Nakamori1^,4, Toshiaki Tsuji1, Tomoya Kato1, Masaki Nakamura1, Toshiyasu Ojima1, Hiroshi Fukuhara2, Yasushi Ino3, Tomoki Todo3 and Hiroki Yamaue1

1 Second Department of Surgery, Wakayama Medical University, Wakayama, Japan

2 Department of Urology, School of Medicine, Kyorin University, Tokyo, Japan

3 Division of Innovative Cancer Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

4 Division of Digestive Surgery, Osaka Minami Medical Center, National Hospital Organization, Kawachinagano, Osaka, Japan

Correspondence to:

Mikihito Nakamori,

email:

[email protected]

Keywords: oncolytic virus; herpes simplex virus; gastric cancer

Received: October 15, 2020 Accepted: January 19, 2021 Published: February 16, 2021

Copyright: © 2021 Matsumura et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Oncolytic virotherapy is an encouraging treatment using herpes simplex virus (HSV) for gastric cancer patients. To treat gastric cancer, we generated and evaluated the efficacy of an attractive type of oncolytic HSV expressing the suppressor of cytokine signaling 3 (SOCS3). We constructed a third-generation type of oncolytic HSV (T-SOCS3) arming with SOCS3 by a bacterial artificial chromosome (BAC) system. We examined the viral replicative intensification and oncolysis of T-SOCS3 for human gastric cancer cell lines ex vivo. T-SOCS3 enhanced its replication and potentiated its cell-killing effect for MKN1 human gastric cancer cell lines, which are resistant to a non-armed third-generation type of oncolytic HSV (T-01) ex vivo. T-SOCS3 also induced the destruction within human gastric cancer specimens. Armed oncolytic HSVs expressing SOCS3 may be an efficacious therapeutic agent for gastric cancer treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27873

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer

Abstract